Nifedipine controlled-release tablets can be combined with hydrochlorothiazide for the treatment of essential hypertension, can be combined with sartan-type or lor-type antihypertensive drugs for the treatment of essential hypertension with stabilized angina pectoris, and can also be combined with Puli type for the treatment of hypertension combined with coronary heart disease. Nifedipine controlled-release tablets have strong dilatation effect on arterial vasculature, while sartan-type and Puli-type antihypertensive drugs can dilate both arteries and veins, and the combination with nifedipine controlled-release tablets has synergistic antihypertensive effect, improving the rate of blood pressure control and standardization rate, and the adverse effects such as ankle edema and accelerated heart rate caused by nifedipine can be partially offset or alleviated by sartan-type or Puli-type antihypertensive drugs. Hydrochlorothiazide can enhance the antihypertensive effect of nifedipine controlled-release tablets by dilating blood vessels, promoting the discharge of water and sodium and lowering blood pressure. Long-term use of nifedipine controlled-release tablets can cause hypokalemia, hyponatremia, hyperglycemia, and hyperuricemia, and the combination with nifedipine can reduce the dosage of the medication and effectively reduce the incidence of adverse reactions, and regular long-term use can also reduce the risk of stroke in patients with high blood pressure. Note that nifedipine controlled-release tablets are contraindicated in pregnant and lactating women, and should be used with caution in patients with severe aortic stenosis, hepatic and renal insufficiency. In addition, when discontinuing the use of calcium antagonists should be gradually reduced in dosage, do not discontinue the use of the drug without a doctor’s instructions. Do not discontinue the medication without a doctor’s instruction. Avoid self-medication to prevent delays.